Screener
Chemours CC Impairment Charges
Impairment Charges at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Chemours in its filing.
Tagged under the XBRL concept us-gaap:RestructuringCostsAndAssetImpairmentCharges.
The source filing: Chemours’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 5:04 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001627223-26-000011
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Loss on extinguishment of debt | 9 | — |
| Amortization of debt issuance costs and issue discounts | 3 | 3 |
| Deferred tax benefit | (11) | (14) |
| Asset-related charges | 1 | 1 |
| Stock-based compensation expense | 7 | 5 |
| Net periodic pension cost (income) | — | — |
| Defined benefit plan contributions | (1) | (4) |
| Other operating charges and credits, net | (14) | 37 |
Item 1. INTERIM CONSOLIDATED FINANCIAL STATEMENTS
FAQ
- What is Chemours's impairment charges?
- Chemours (CC) reported impairment charges of $1M in Q1 2026.
- How has Chemours's impairment charges changed year-over-year?
- Chemours's impairment charges decreased by 0.0% year-over-year, from $1M to $1M.
- What does impairment charges mean?
- Non-cash asset impairment charges added back in the operating cash flow reconciliation since they don't represent cash outflows.
Ask your AI about Chemours's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude